Applications of SELDI-TOF technology in cancer biomarkers discovery

Romanian Biotechnological Letters

Volumn 15, Issue 5, 2010, Pages 5654-5667

  Popescu, Ionela Daniela ^a   Albulescu, Radu ^a,b   Raducan, Elena ^a   Dinischiotu, Anca ^c   Tanase, Cristiana ^a  

^a VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^b NATIONAL INSTITUTE FOR CHEMICAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (Romania)

^c UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Biomarkers; Cancer; Early detection; Mass spectrometry; Proteomics; SELDI TOF

Indexed keywords

EID: 78649722395     PISSN: 12245984     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. National Vital Statistics Report 50 (15) 2002.
2. L.C. WHELAN, K.A.R. POWER, D.T MCDOWELL, J. KENNEDY, W.M. GALLAGHER, Applications of SELDI-MS technology in oncology, Molecular Diagnosis. J. Cell. Mol. Med., 12 (5A), 1535-1547 (2008).
3. M. LU, K. F. FAULL, J.P. WHITELEGGE, J. HE, D. SHEN, R.E. SAXTON, H.R. CHANG, Proteomics and Mass Spectrometry for Cancer Biomarker Discovery. Biomarker Insights, 2, 347-360 (2007).
4. V. SEIBERT, M.P. EBERT, T. BUSCHMANN, Advances in clinical cancer proteomics: SELDI-ToF-mass spectrometry and biomarker discovery. Briefings in functional genomics and proteomics. 4(1), 16-26 (2005).
5. The Innovative Medicines Initiative (IMI), Strategic Research Agenda "Creating Biomedical R&D Leadership for Europe to Benefit Patients and Society" http://www.efpia.org/4_pos/SRA.pdf, 40 (2006).
6. A.J. ATKINSON, W.A. COLBURN, V.G. DEGRUTTOLA, D.L. DEMETS, G.J. DOWNING, D.F. HOTH, J.A. OATES, C.C. PECK, R.T. SCHOOLEY, B.A. SPILKER, J. WOODCOCK, S.L. ZEGER, Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clinical Pharm. & Therapeutics, 69(3), 89-95 (2001).
7. M.A. TAINSKY, Genomic and proteomic biomarkers for cancer: a multitude of opportunities, Biochim Biophys Acta, 1796(2), 176-93 (2009).
8. T.J. LEY, E.R. MARDIS, L. DING, B. FULTON, M.D. MCLELLAN, K. CHEN, D. DOOLING, B.H. DUNFORD-SHORE, S. MCGRATH, M. HICKENBOTHAM, L. COOK, R. ABBOTT, D.E. LARSON, D.C. KOBOLDT, C. POHL, S. SMITH, A. HAWKINS, S. ABBOTT, D. LOCKE, L.W. HILLIER, T. MINER, L. FULTON, V. MAGRINI, T. WYLIE, J. GLASSCOCK, J. CONYERS, N. SANDER, X. SHI, J.R. OSBORNE, P. MINX, D. GORDON, A. CHINWALLA, Y. ZHAO, R.E. RIES, J.E. PAYTON, P. WESTERVELT, M.H. TOMASSON, M. WATSON, J. BATY, J. IVANOVICH, S. HEATH, W.D. SHANNON, R. NAGARAJAN, M.J. WALTER, D.C. LINK, T.A. GRAUBERT, J.F. DIPERSIO, R.K. WILSON, DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 456(7218), 66-72 (2008).
9. L. DING, G. GETZ, D.A. WHEELER, E.R. MARDIS, M.D. MCLELLAN, K. CIBULSKIS, C. SOUGNEZ, H. GREULICH, D.M. MUZNY, M.B. MORGAN, L. FULTON, R.S. FULTON, Q. ZHANG, M.C. WENDL, M.S. LAWRENCE, D.E. LARSON, K. CHEN, D.J. DOOLING, A. SABO, A.C. HAWES, H. SHEN, S.N. JHANGIANI, L.R. LEWIS, O. HALL, Y. ZHU, T. MATHEW, Y. REN, J. YAO, S.E. SCHERER, K. CLERC, G.A. METCALF, B. NG, A. MILOSAVLJEVIC, M.L. GONZALEZ-GARAY, J.R. OSBORN, R. MEYER, X. SHI, Y. TANG, D.C. KOBOLDT, L. LIN, R. ABBOTT, T.L. MINER, C. POHL, G. FEWELL, C. HAIPEK, H. SCHMIDT, B.H. DUNFORD-SHORE, A. KRAJA, S.D. CROSBY, C.S. SAWYER, T. VICKERY, S. SANDER, J. ROBINSON, W. WINCKLER, J. BALDWIN, L.R. CHIRIEAC, A. DUTT, T. FENNELL, M. HANNA, B.E. JOHNSON, R.C. ONOFRIO, R.K. THOMAS, G. TONON, B.A. WEIR, X. ZHAO, L. ZIAUGRA, M.C. ZODY, T. GIORDANO, M.B. ORRINGER, J.A. ROTH, M.R. SPITZ, I. WISTUBA, B. OZENBERGER, P.J. GOOD, A.C. CHANG, D.G. BEER, M.A. WATSON, M. LADANYI, S. BRODERICK, A. YOSHIZAWA, W.D. TRAVIS, W. PAO, M.A. PROVINCE, G.M. WEINSTOCK, H.E. VARMUS, S.B. GABRIEL, E.S. LANDER, R.A. GIBBS, M. MEYERSON, R.K. WILSON, Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455, 1069-1075 (2008).
10. R.J. LEARY, J.C. LIN, J. CUMMINS, S. BOCA, L.D. WOOD, D.W. PARSONS, S. JONES, T. SJÖBLOM, B.H. PARK, R. PARSONS, J. WILLIS, D. DAWSON, J.K. WILLSON, T. NIKOLSKAYA, Y. NIKOLSKY, L. KOPELOVICH, N. PAPADOPOULOS, L.A. PENNACCHIO, T.L. WANG, S.D. MARKOWITZ, G. PARMIGIANI, K.W. KINZLER, B. VOGELSTEIN, E. VELCULESCU, Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc. Natl. Acad. Sci. U. S. A., 105, 16224-16229 (2008).
11. S. OKUDA, T. YAMADA, M.A. HAMAJIMA, M. ITOH, T. KATAYAMA, P. BORK, S. GOTO, M. KANEHISA. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res. 36, W423 - 6 (Web Server issue) (2008).
12. I. SEGOTA, N. BARTONICEK, K. VLAHOVICEK, MADNet: microarray database network web server, Nucleic. Acids. Res, 36, W332-W335 (Web Server issue) (2008).
13. M.O. HOQUE, Q. FENG, P. TOURE, A. DEM, C.W. CRITCHLOW, S.E. HAWES, T. WOOD, C. JERONIMO, ROSENBAUM E, J. STERN, M. YU, B. TRINK, KIVIAT NB, D. SIDRANSKY, Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer, J. Clin. Oncol. 24, 4262-4269, (2006).
14. Y. MURAKI, K. BANNO, M. YANOKURA, Y. KOBAYASHI, M. KAWAGUCHI, H. NOMURA, A. HIRASAWA, N. SUSUMU, D. AOKI, Epigenetic DNA hypermethylation: clinical applications in endometrial cancer. Oncol Rep., 22(5), 967-72 (2009).
15. C.H. LAWRIE, S. GAL, H.M. DUNLOP, B. PUSHKARAN, A.P. LIGGINS, K. PULFORD, A.H. BANHAM, F. PEZZELLA, J. BOULTWOOD, J.S. WAINSCOAT, HATTON CS, A.L. HARRIS, Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma, Br. J. Haematol., 141, 672-675 (2008).
16. M. ROESSLER, W. ROLLINGER, L. MANTOVANI-ENDL, M.L. HAGMANN, S. PALME, P. BERNDT, A.M. ENGEL, M. PFEFFER, J. KARL, H. BODENMÜLLER, J. RÜSCHOFF, T. HENKEL, G. ROHR, S. ROSSOL, W. RÖSCH, H. LANGEN, W. ZOLG, M. TACKE, Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics, 5, 2092-2101, (2006).
17. J. MARTOSELLA, N. ZOLOTARJOVA, H. LIU, G. NICOL, BE BOYES, Reversed-phase high performance liquid chromatographic prefractionation of immunodepleted human serum proteins to enhance mass spectrometry identification of lowerabundant proteins. J. Proteome. Res., 4, 1522-1537, (2005).
18. V. FACA, M. CORAM, D. PHANSTIEL, V. GLUKHOVA, Q. ZHANG, M. FITZGIBBON, M. MCINTOSH, S. HANASH, Quantitative analysis of acrylamide labeled serum proteins by LC-MS/MS. J. Proteome. Res., 5, 2009-2018, (2006).
19. V.P. ANDREEV, L. LI, T. REJTAR, Q. LI, J.G. FERRY, B.L. KARGER, New algorithm for 15N/14N quantitation with LC-ESI-MS using an LTQ-FT mass spectrometer. J. Proteome Res., 52039-2045, (2006).
20. M. MERCHANT, S.R. WEINBERGER, Recent advancements in surface enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis, 21, 1164-1177,(2000).
21. E.F. PETRICOIN, K.C. ZOON, E.C. KOHN, J.C. BARRETT, L.A. LIOTTA, Clinical proteomics: translating benchside promise into bedside reality, Nat Rev Drug Discov., 1, 683-695 (2002).
22. B.B. HAAB, Antibody arrays in cancer research. Molecular & Cellular Proteomics. 4, 377-383 (2005).
23. M. SANCHEZ-CARBAYO, N.D. SOCCI, J.J. LOZANO, B.B. HAAB, C. CORDON-CARDO, Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol. 168, 93-103 (2006).
24. T.W. HUTCHENS, T.T. YIP, New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom.7, 576-580 (1993).
25. H.J. ISSAQ, D.T. VEENSTRA, P.T. CONRADS, D. FELSCHOW, The SELDI-TOF MS Approach to Proteomics: Protein Profiling and Biomarker Identification. Biochemical and Biophysical Research Communications. 292, 587-592 (2002).
26. J.A.P. BONS, D. DE BOER, M.P. VAN DIEIJEN-VISSER, W KWH WODZIG, Standardization of calibration and quality control using surface enhanced laser desorption ionization-time of flight-mass spectrometry. Clinica Chimica Acta, 366, 249-256 (2006).
27. K. SOMASUNDARAM, M. B. NIJAGUNA, D. M. KUMAR, Serum proteomics of glioma: methods and applications. Expert Rev. Mol. Diagn., 9(7), 695-707 (2009).
28. M. NEAGU, C. CONSTANTIN, G. MANDA, D. POPESCU, V. UNGUREANU, D. TATU, M. PANA, D.L. RADU, A. BULMAN, K. VORGIAS, O. TSITSILONIS, W. VOELTER, SELDI -ToF-MS for prothymosin - alpha detection as bacterial infection apoptosis marker -Nato SfP Project. Medimond -Monduzzi Editore, www.monduzzi.com - pg. 419-422, (2009).
29. L.F. STEEL, B.B. HABB, S.M. HANASH, Methods of comparative proteomic profiling for disease diagnostics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 815(1-2), 275-284 (2005).
30. C. PISTOL TǍNASE, Caveolin -1 - A Marker For Pancreatic Cancer Diagnosis. Expert review of molecular diagnostics, 8(4), 395-404 (2008).
31. C. PISTOL-TǍNASE, E. RADUCAN, S.O. DIMA, L. ALBULESCU, A. IONITA, M. POROSCHIANU., L.M.. CRUCERU, E. CODOREAN, T.M. NEAGU, I. POPESCU, Assessment of soluble angiogenic markers in pancreatic cancer. Biomarkers in Medicine, 2(5), 447-455 (2008).
32. K. HONDA, Y. HAYASHIDA, T. UMAKI, T. OKUSAKA, T. KOSUGE, S. KIKUCHI, M. ENDO, A. TSUCHIDA, T. AOKI, T. ITOI, F. MORIYASU, S. HIROHASHI, T. YAMADA, Possible Detection of Pancreatic Cancer by Plasma Protein Profiling. Cancer Res, 65: (22), 10613-10622 (2005).
33. C. PISTOL TǍNASE, M. NEAGU, R. ALBULESCU, E. CODOREAN, S.O. DIMA, Biomarkers in the diagnosis and early detection of pancreatic cancer. Expert Opinion On Medical Diagnostics, 3 (5), 533-546 (2009).
34. M. EHMANN, K. FELIX, D. HARTMANN, M. SCHNOLZER, M. NEES, S. VORDERWULBECKE, R. BOGUMIL, M.W. BUCHLER, H. FRIESS, Identification of Potential Markers for the Detection of Pancreatic Cancer Through Comparative Serum Protein Expression Profiling. Pancreas., 34, 205-214 (2007).
35. C. GE, N. MA, D. YAO, F. LUAN, C. HU, Y. LI, Y. LIU, A Serum Biomarker Model to Diagnose Pancreatic Cancer Using Proteomic Fingerprint Technology. Chin J Clin Oncol., 5, 200-205 (2008).
36. J. KOOPMANN, Z. ZHANG, N. WHITE, J. ROSENZWEIG, N. FEDARKO, S. JAGANNATH,. M.I. CANTO, C. J YEO, D.W. CHAN, M. GOGGINS, Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry. Clinical Cancer Research, 10, 860-868 (2004).
37. P. HEWITSON, P. GLASZIOU, L. IRWIG, B. TOWLER, E. WATSON, Screening for colorectal cancer using the faecal occult blood test. Hemoccult, Cochrane Database Systematic Reviews., 1-25 (2007).
38. M. MOSHKOWITZ, N. ARBER, Emerging technologies in colorectal cancer screening. Surg Oncol Clin N Am, 14(4), 723-746 (2005).
39. D.G. WARD, S. NYANGOMA, H. JOY, E. HAMILTON, W. WEI, C. TSELEPIS, N. STEVEN, M.J.O. WAKELAM, P.J. JOHNSON, T. ISMAIL, A. MARTIN, Proteomic profiling of urine for the detection of colon cancer, Proteome Science, 6(1), 19-34 (2008).
40. D.G. WARD, N. SUGGETT, Y. CHENG, W. WEI, H. JOHNSON, L.J. BILLINGHAM, T. ISMAIL, M.J.O. WAKELAM, P.J. JOHNSON, A. MARTIN, Identification of serum biomarkers for colon cancer by proteomic analysis, British Journal of Cancer, 94(12), 1898-1905 (2006).
41. J.Y.M.N. ENGWEGEN, A.C.T.M. DEPLA, M.E. SMITS, A. CATS, H. TUYNMAN, H.A. VAN HEUKELEM, P. SNEL, W. MEULEMAN, L.F. WESSELS, J.H.M. SCHELLENS, J.H. BEIJNEN, Detection of Colorectal Cancer by Serum and Tissue Protein Profiling: A Prospective Study in a Population at Risk. Biomarker Insights, 3, 375-385 (2008).
42. J.K.YU, Y.D. CHEN, S. ZHENG, An integrated approach to the detection of colorectal cancer utilizing proteomics and bioinformatics. World J. Gastroenterol., 10(21), 3127-31( 2004).
43. X.P. LIU, J. SHEN, Z.F. LI, L. YAN, J. GU, A serum proteomic pattern for the detection of colorectal adenocarcinoma using surface enhanced laser desorption and ionization mass spectrometry, Cancer Invest., 24(8), 747-53 (2006).
44. D.G. WARD, K. ROBERTS, M.J. BROOKES, H. JOY, A. MARTIN, T. ISMAIL, R. SPYCHAL, T. IQBAL, C. TSELEPIS, Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol., 14(9), 1339-45 (2008).
45. L.C. WHELAN, K.A.R. POWER, D.T. MCDOWELL, J. KENNEDY, W.M. GALLAGHER, Applications of SELDI-MS technology in oncology. J. Cell. Mol. Med, 12( 5):1535-1547(2008).
46. C. MELLE, G. ERNST, R. WINKLER, B. SCHIMMEL, J.P. KLUSSMANN, C. WITTEKINDT, O. GUNTINAS-LICHIUS, F. VON EGGELING, Proteomic analysis of human papillomavirus-related oral squamous cell carcinoma: Identification of thioredoxin and epidermal-fatty acid binding protein as upregulated protein markers in microdissected tumor tissue. Proteomics, 9, 2193-2201(2009).
47. Y.F.WONG, T.H. CHEUNG, K.W.K. LO., V.W. WANG., C.S. CHAN, T.B. NG, T.K.H. CHUNG, S.C. MOK, Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix.Cancer Letters, 211(2), 227-234 (2004).
48. X. ZHU, J. LV, L. YU, X. ZHU, J. WU, S. ZOU, S. JIANG, Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecologic Oncology, 112(1), 248-256 (2009).
49. T. XIA, Z.G. ZHENG, Y. GAO, H.Z. MOU, S.H. XU, P. ZHANG, J.Q. ZHU, Application of SELDI-TOF serum proteome profiling in cervical squamous cell carcinoma. Ai Zheng, 27(3), 279-82 (2008).
50. S.N. CAI, G.B. LIU, X.H. GUO, J.G. CHEN, J. ZHANG, Y.L. WU, W.J. LIANG, R.C. LUO, Proteinchip-flight mass spectrometry for screening differentially expressed proteins in the serum of cervical cancer patients. Nan Fang Yi Ke Da Xue Xue Bao, 29(1), 32-5 (2009).
51. E.F. PETRICOIN, K.C. ZOON, E.C. KOHN, Clinical proteomics: translating benchside promise into bedside reality, Nat Rev Drug Discov, 1, 683-695 (2002).
52. W.E. GRIZZLE, O.J. SEMMES, W.L. BIGBEE, The need from review and understanding of SELDI/MALDI mass spectroscopy data prior to analysis, Cancer Inform, 1, 86-97 (2005).
53. D.M. GOOD, V. THONGBOONKERD, J. NOVAK, J.P. SCHANSTRA, J.J. COON, A. DOMINICZAK, H. MISCHAK, Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future, J Proteome Res., 6, 4549-4555 (2007).
54. A.K. CALLESEN, W. VACH, P.E. JORGENSEN, S. COLD, Q. TAN, R. DEPONT CHRISTENSEN, O. MOGENSEN, T.A. KRUSE, O.N. JENSEN, J.S. MADSEN, Combined experimental and statistical strategy for mass spectrometry based serum protein profiling for diagnosis of breast cancer: a case-control study, J Proteome Res., 7, 1419-1426 (2008).
55. M.E. NOO, A. DEELDER, W.M. VAN DER WERFF, A. OZALP, B. MERTENS, R. TOLLENAAR, MALDITOF serum protein profiling for the detection of breast cancer, Onkologie, 29, 501-506 (2006).
56. C. LARONGA, S. BECKER, P. WATSON, B. GREGORY, L. CAZARES, H. LYNCH, R.R. PERRY, G.L. WRIGHT JR, R.R. DRAKE, O.J. SEMMES, SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers, Dis Markers., 19, 229-238 (2003).
57. M.C. GAST, E.J. VAN DULKEN, T.K. VAN LOENEN, F. KINGMA-VEGTER, J. WESTERGA, C.C. FLOHIL, J.C. KNOL, C.R. JIMENEZ, C.H. VAN GILS, L.F. WESSELS, J.H. SCHELLENS, J.H. BEIJNEN, Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling, Int J Biol Markers., 24(3), 130-41(2009).
58. M.C. GAST, C.H. VAN GILS, L.F. WESSELS, N. HARRIS, J.M. BONFRER, E.J. RUTGERS, J.H. SCHELLENS, J.H. BEIJNEN, Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS, Oncol Rep., 22(1), 205-13 (2009).
59. R.J. SIMPSON, O.K. BERNHARD, D.W. GREENING, R.L. MORITZ, Proteomics - driven cancer biomarker discovery: looking to the future, Curr Opin Chem Biol.,12, 72-77 (2008).
60. M.C. GAST, J.H. SCHELLENS, J.H. BEIJNEN, Clinical proteomics in breast cancer: a review, Breast Cancer Res Treat., 116, 17-29 (2009).
61. T. NAKAGAWA, S.K. HUANG, S.R. MARTINEZ, A.N. TRAN, D. ELASHOFF, X. YE, R.R. TURNER, A.E. GIULIANO, D.S. HOON, Proteomic profiling of primary breast cancer predicts axillary lymph node metastasis, Cancer Res., 66, 11825-11830 (2006).
62. F. TRAUB, H. FEIST, H.H. KREIPE, A. PICH, SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas, Pathol Res Pract, 201, 763-770 (2005).
63. K. SOMASUNDARAM, M.B. NIJAGUNA, D.M. KUMAR, Serum proteomics of glioma: methods and applications, Expert Rev. Mol. Diagn., 9(7), 695-707 (2009).
64. V. PETRIK, S. SAADOUN, A. LOOSEMORE, J. HOBBS, K.S. OPSTAD, J. SHELDON, E. TARELLI, F.A. HOWE, B. BELL, M.C. PAPADOPOULOS, Serum α2-HS Glycoprotein Predicts Survival in Patients with Glioblastoma, Clinical Chemistry, 54(4), 713-722 (2008).
65. H. ZHANG, G. WU, H. TU, Discovery of serum biomarkers in astrocytoma by SELDI-TOF MS and proteinchip technology, J. Neurooncol., 84(3), 315-332 (2007).
66. J. LIU, S. ZHENG, J. YU, J. ZHANG, Z. CHEN, Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor, Journal of Zhejiang University SCIENCE, 6B(1), 4-10 (2005).
67. J. CARON, A. MANGÉ, B. GUILLOT, J. SOLASSOL, Highly sensitive detection of melanoma based on serum proteomic profiling, J Cancer Res Clin Oncol, 135, 1257-1264 (2009).
68. M. NEAGU, C. CONSTANTIN, G. MANDA, I. MARGARITESCU, Biomarkers of metastatic melanoma, Biomarkers in Medicine, 3(1), 71-89 (2009)
69. R. LAKOMY, K. GREPLOVA, R. PILNY, E. BUDINSKA, D. VALIK, A. POPRACH, R. NEMECEK, R. VYZULA, Profiles of low-molecular proteome spectrum obtained through SELDI-TOF mass spectrometry in the sera of patients with metastatic malignant melanoma:pilot study, Klin Onkol., 22(5), 228-32 (2009).
70. L.L. WILSON, L. TRAN, D.L. MORTON, D.S. HOON, Detection of differentially expressed proteins in early-stage melanoma patients using SELDI-TOF mass spectrometry, John Wayne Cancer Institute Ann NY Acad Sci, 1022, 317-22 (2004).